Skip to main content
Clinical Trials/NCT03688594
NCT03688594
Unknown
Not Applicable

Non Invasive Prenatal Test of Rare Genetic Diseases: Application to Rare Intellectual Disabilities

University Hospital, Strasbourg, France1 site in 1 country60 target enrollmentMay 22, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Genetic Disorders in Pregnancy
Sponsor
University Hospital, Strasbourg, France
Enrollment
60
Locations
1
Primary Endpoint
Detection yield of fetal paternally transmitted single nucleotid variations (SNV) in free cell maternal DNA Absence of non fetal paternally transmitted single nucleotid variations (SNV) in maternal free cell DNA (cfDNA)
Last Updated
7 years ago

Overview

Brief Summary

The aim of this study is to evaluate performances of a NIPT test based onto the study of the maternal blood to search known genetic mutations already detected in the family and potentially inherited by the fetus. This test will avoid an invasive prenatal diagnosis in those families with a known genetic risk.

The performance of this test will be evaluated in terms of sensitivity and specificity with an adapted statistic model.

Secondary objectives of the protocol are

  • To adapt NIPT to small DNA quantity (5-50 ng)
  • To adapt bioinformatics pipeline to low rate of mosaicism
  • To develop a tool to quantify the fetal fraction
  • To evaluate the robustness of the method

This test is based onto capture and high throw put sequencing adapted to cell free plasmatic DNA of pregnant women in order to detect point mutation present in her fetus. This approach has been previously described for others clinical applications such as liquid biopsy in cancers but not for NIPT analysis.

Registry
clinicaltrials.gov
Start Date
May 22, 2018
End Date
May 23, 2019
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
University Hospital, Strasbourg, France
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Couple (father, mother) \> 18 ans
  • Pregnant woman (\> 12-15 weeks of gestation) with a fetal sampling needed in standard care.
  • informed consent obtained
  • couple affiliated to the social insurance in France

Exclusion Criteria

  • DNA extraction failure
  • Absence of informed consent
  • Father or mother placed under judicial protection or under guardianship or tutorship

Outcomes

Primary Outcomes

Detection yield of fetal paternally transmitted single nucleotid variations (SNV) in free cell maternal DNA Absence of non fetal paternally transmitted single nucleotid variations (SNV) in maternal free cell DNA (cfDNA)

Time Frame: Measurement will be performed at the end of the protocol (12 months)

Secondary Outcomes

  • Comparison of SNV detection efficiency of several bioinformatics pipeline Robustness evaluation in function of - Fetal percent in cfDNA - Genomic region - Initial input of cfDNA(Measurement will be performed at the end of the protocol (12 months))

Study Sites (1)

Loading locations...

Similar Trials